Join a walk for Crohn's & Colitis.
Register for a walk near you!
Train for a half marathon while raising funds for crucial research. Teams
forming now -- find yours today!
FDA approves Humira to treat ulcerative colitis
The U.S. Food and Drug Administration today expanded the approved use of Humira (adalimumab) to include treatment of moderate-to-severe ulcerative colitis in adults. Humira is approved to control ulcerative colitis when immunosuppressant medicines like corticosteroids, azathioprine, and 6-mercaptopurine have not worked. The drug is an anti-tumor necrosis factor (TNF) that blocks proteins that play an important role in abnormal inflammatory and immune responses. The drug was approved for Crohn's disease in 2007.
For more information, please see the FDA's website.
- Expanding IBD Research Through Collaboration
- Gut Microbiome Points To Cures and Treatment for IBD
- FDA Approves Takeda’s Entyvio™ (vedolizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease
- Improving Quality of Care for IBD Patients at First IBD2020 USA Meeting
- Largest Microbiome Study on Newly Diagnosed Patients Gives Insight Into Crohn’s Disease and Shows Antibiotic Treatment May Worsen Disease